Jay M. Edelberg

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Iacopo Olivotto, Artur Oręziak, Roberto Barriales‐Villa et al. · The Lancet · 2020 · 1.1K citations · Full text

Cardiomyopathy, Structural Heart Disease, Cardiovascular Disease +2

Loss of SR-BI Expression Leads to the Early Onset of Occlusive Atherosclerotic Coronary Artery Disease, Spontaneous Myocardial Infarctions, Severe Cardiac Dysfunction, and Premature Death in Apolipoprotein E–Deficient Mice

Anne Braun, Bernardo L. Trigatti, Mark J. Post et al. · Circulation Research · 2002 · 486 citations

Vascular Disease, Sr-bi Expression, Hyperlipidemia +20

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy

Milind Y. Desai, Anjali Owens, Jeffrey B. Geske et al. · Journal of the American College of Cardiology · 2022 · 319 citations · Full text

Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy

Carolyn Y. Ho, Matthew E. Mealiffe, Richard G. Bach et al. · Journal of the American College of Cardiology · 2020 · 316 citations · Full text

Vascular Bed–specific Expression of an Endothelial Cell Gene Is Programmed by the Tissue Microenvironment

William C. Aird, Jay M. Edelberg, Hartmut Weiler-Guettler et al. · The Journal of Cell Biology · 1997 · 265 citations · Full text